Phase 2
N=18
Positional Therapy After Stroke
Sleep Apnea · Stroke
Bottom Line
View on ClinicalTrials.gov: NCT01047709 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Jun 2013
Primary outcome: Primary: Apnea-hypopnea Index — 27; 39 events/hr — p=0.011
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Positional therapy including the use of a special pillow (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Michigan
- Primary completion
- Feb 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Apnea-hypopnea Index |
27; 39 | 0.011 sig |
Summary
Stroke is the leading cause of adult disability and the third leading cause of death in the United States. Unfortunately, there are few therapies that have been proven to improve stroke outcome. Sleep apnea is an emerging stroke risk factor and has a well established association with higher mortality and poor functional outcome following stroke. Over half of acute stroke patients have sleep apnea, suggesting that it may be a important target for therapy. Attenuation of sleep apnea severity may result in improved stroke outcomes. However, the standard treatment for sleep apnea is not well-tolerated among stroke patients. An alternative treatment is avoidance of supine sleep. Supine sleep is very common in acute stroke patients, and therefore this treatment may have particular relevance to the stroke population. The proposed study will be conducted in two phases. The first phase is a randomized, crossover design in which acute stroke patients will be given positional treatment (to avoid supine sleep) on one night during their stroke hospitalization. This will be compared with another night of sleeping without positional therapy. The order of treatments (standard vs positional therapy) will be random. The first phase will demonstrate the proof of concept: that stroke patients given positional therapy to avoid supine sleep will (1) sleep less on their backs, and (2) will have improved sleep apnea parameters with positional therapy. In the second phase, those identified to have sleep apnea will be randomized to receive positional therapy at home for three months, or standard therapy. This second phase will demonstrate the adherence/feasibility of three months of positional therapy, and will allow us to estimate effect size based on a functional outcome measure. The data obtained from this pilot clinical trial are essential to plan a large efficacy study.
Eligibility Criteria
Inclusion Criteria
- Age 18 or older
- Probable ischemic stroke within prior 14 days
Exclusion Criteria
- Any medical condition precluding the avoidance of supine posture or dictating the need for a particular position.
- Current use of CPAP (or other PAP), mechanical ventilation, or supplemental oxygen.
Data sourced from ClinicalTrials.gov (NCT01047709). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.